Record overview
Status and phase
Status: COMPLETED
Phase: PHASE1, PHASE2
Sponsor: ImmunoGen, Inc.
Condition: Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
NCT02606305
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: large_enrollment_target_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.